Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida.
Gastroenterology. 2020 Apr;158(5):1232-1249.e3. doi: 10.1053/j.gastro.2019.12.034. Epub 2020 Jan 13.
With a worldwide prevalence of 15%, chronic constipation is one of the most frequent gastrointestinal diagnoses made in ambulatory medicine clinics, and is a common source cause for referrals to gastroenterologists and colorectal surgeons in the United States. Symptoms vary among patients; straining, incomplete evacuation, and a sense of anorectal blockage are just as important as decreased stool frequency. Chronic constipation is either a primary disorder (such as normal transit, slow transit, or defecatory disorders) or a secondary one (due to medications or, in rare cases, anatomic alterations). Colonic sensorimotor disturbances and pelvic floor dysfunction (such as defecatory disorders) are the most widely recognized pathogenic mechanisms. Guided by efficacy and cost, management of constipation should begin with dietary fiber supplementation and stimulant and/or osmotic laxatives, as appropriate, followed, if necessary, by intestinal secretagogues and/or prokinetic agents. Peripherally acting μ-opiate antagonists are another option for opioid-induced constipation. Anorectal tests to evaluate for defecatory disorders should be performed in patients who do not respond to over-the-counter agents. Colonic transit, followed if necessary with assessment of colonic motility with manometry and/or a barostat, can identify colonic dysmotility. Defecatory disorders often respond to biofeedback therapy. For specific patients, slow-transit constipation may necessitate a colectomy. No studies have compared inexpensive laxatives with newer drugs with different mechanisms. We review the mechanisms, evaluation, and management of chronic constipation. We discuss the importance of meticulous analyses of patient history and physical examination, advantages and disadvantages of diagnostic testing, guidance for individualized treatment, and management of medically refractory patients.
慢性便秘的全球患病率为 15%,是在门诊医学诊所中最常见的胃肠道诊断之一,也是美国肠胃病学家和结直肠外科医生转诊的常见原因。患者的症状各不相同;用力、不完全排空和肛门直肠阻塞感与粪便频率减少同样重要。慢性便秘要么是原发性疾病(如传输正常、传输缓慢或排便障碍),要么是继发性疾病(由药物引起,在极少数情况下,是由解剖结构改变引起)。结肠感觉运动障碍和盆底功能障碍(如排便障碍)是最广泛认可的发病机制。根据疗效和成本,便秘的治疗应从膳食纤维补充剂和刺激性及/或渗透性泻药开始,如有必要,可随后使用肠分泌剂和/或促动力剂。外周作用 μ 阿片受体拮抗剂是治疗阿片类药物引起的便秘的另一种选择。对于那些对非处方药物没有反应的患者,应进行肛门直肠检查以评估排便障碍。如果有必要,可以进行结肠传输检查,如果有必要,还可以进行测压和/或压力容积检查来评估结肠动力,可以识别结肠动力障碍。排便障碍通常对生物反馈治疗有反应。对于特定患者,慢传输性便秘可能需要结肠切除术。没有研究比较过廉价的泻药与具有不同作用机制的新型药物。我们回顾了慢性便秘的发病机制、评估和治疗。我们讨论了仔细分析患者病史和体格检查、诊断测试的优缺点、个体化治疗指导以及治疗难治性患者的重要性。